TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

PHASE3RecruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2030

Conditions
Ovarian Germ Cell CancerOvarian NeoplasmsOvarian Cancer
Interventions
DRUG

Paclitaxel

Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

DRUG

Carboplatin

and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.

DRUG

Bleomycin

Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.

DRUG

Etoposide

Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.

DRUG

Cisplatin

Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
collaborator

Huazhong University of Science and Technology

OTHER

collaborator

Zhejiang University

OTHER

collaborator

Sun Yat-sen University

OTHER

lead

Beihua Kong

OTHER